Ultralow Dose PET Imaging for PSMA Expression
Recruiting now · Phase 2
Conditions studied: Healthy Volunteer, Prostate CA
In brief
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for prostate cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-DCFPyL and be imaged on a new type of high sensitivity PET scanner for up to 3 hours
Key facts
- Study ID
- NCT06904313
- Run by
- Akiva Mintz
- People needed
- 200
- Starts
- 2025-05-12
- Expected to finish
- 2030-06-30
- Last updated by the study team
- 2025-06-04
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Age ≥18 years.
- Ability to provide informed consent and comply with study procedures.
- For female participants:
- Must not be pregnant or breastfeeding.
- Negative pregnancy test required for women of childbearing potential.
You may not qualify if…
- Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 mSv total).
- More than four prior enrollments in this study.
- Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan
- Medication \& Prior Treatment Exclusions
- Concurrent PSMA-targeted therapy (e.g., lutetium-177).
- Pregnant or breastfeeding individuals (negative pregnancy test required)
- Inability to provide informed consent
- Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.
Where it is running
- Nuclear Imaging Institute — Englewood, New Jersey, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.